Apellis Pharmaceuticals (APLS) Prices 9.5M Share Offering at $37/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Apellis Pharmaceuticals (APLS) PT Raised to $62 at Oppenheimer
January 8, 2020 9:25 AM ESTOppenheimer analyst Justin Kim raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $62.00 (from $52.00) while maintaining a Outperform rating.
The analyst commented, "We are reiterating our Outperform rating and increasing our PT to $62 on APLS, following positive Phase 3 PEGASUS data in PNH... More
Apellis Pharmaceuticals (APLS) PT Raised to $80 at Citi
January 8, 2020 6:08 AM ESTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $80.00 (from $37.00) while maintaining a Buy rating.... More
Apellis Pharmaceuticals (APLS) PT Raised to $36 at Credit Suisse
January 8, 2020 6:03 AM ESTCredit Suisse analyst Tiago Fauth raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $36.00 (from $33.00) while maintaining a Neutral rating.... More
Apellis Pharmaceuticals (APLS) PT Raised to $36 at Credit Suisse
January 7, 2020 4:17 PM ESTCredit Suisse analyst Tiago Fauth raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $36.00 (from $33.00) while maintaining a Neutral rating.
The analyst comments "Todays PEGASUS efficacy data came in ahead of investors expectations, though it doesnt meaningfully change our view on... More
Apellis Pharmaceuticals (APLS) Announces Proposed 7M Share Common Offering
January 7, 2020 4:13 PM ESTApellis Pharmaceuticals, Inc. (NASDAQ: APLS) today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to... More
Apellis Pharmaceuticals (APLS) files automatic mixed securities shelf
January 7, 2020 4:05 PM ESTApellis Pharmaceuticals (NASDAQ: APLS) files automatic mixed securities shelf
... MoreApellis Pharmaceuticals (APLS) PT Raised to $62 at Oppenheimer
January 7, 2020 3:26 PM ESTOppenheimer analyst Justin Kim raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $62.00 (from $52.00) while maintaining a Outperform rating.
... MoreApellis Pharmaceuticals (APLS) PT Raised to $80 at Citi
January 7, 2020 2:57 PM ESTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $80.00 (from $37.00) while maintaining a Buy rating.
... MorePre-Open Stock Movers 01/07: (APLS) (TYME) (APA) Higher (CRNC) (ITCI) (ARE) Lower (more...)
January 7, 2020 9:30 AM ESTToday's Pre-Open Stock Movers
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) 36.8% HIGHER; Announced positive results from the Phase 3 PEGASUS study evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Top-line data show that pegcetacoplan met the studys primary efficacy endpoint, demonstrating... More
Apellis Pharmaceuticals (APLS) PT Raised to 'Street High' $70 at Baird
January 7, 2020 9:08 AM ESTBaird analyst Brian Skorney raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to a 'Street High' $70.00 (from $45.00) while maintaining a Outperform rating.
... MoreApellis Pharmaceuticals (APLS) Data Exceeded Expectations, Expect Shares to Fly - Cantor Fitzgerald
January 7, 2020 8:08 AM ESTCantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating and $54.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS) following positive data.
Merle commented, "We think positive Ph3 data well exceeds investor expectations. As we wrote in our preview (link), we think investors... More
Alexion Pharma (ALXN) Shares on Watch After Positive Data from Competitor Apellis Pharmaceuticals (APLS) in PNH
January 7, 2020 7:10 AM ESTAlexion Pharma (NASDAQ: ALXN) Shares on Watch After Positive Data from Competitor Apellis Pharmaceuticals (NASDAQ: APLS) in PNH
... MoreApellis Pharmaceuticals (APLS) to Resume Trading at 7:30 am
January 7, 2020 7:07 AM ESTApellis Pharmaceuticals (NASDAQ: APLS) to Resume Trading at 7:30 am
... MoreApellis Pharmaceuticals (APLS) Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with PNH Met the Primary Efficacy Endpoint
January 7, 2020 7:01 AM ESTApellis... More
Apellis Pharmaceuticals (APLS) Halted, News Pending
January 7, 2020 6:58 AM ESTApellis Pharmaceuticals (NASDAQ: APLS) Halted, News Pending
... MoreSVB Leerink Starts Apellis Pharmaceuticals (APLS) at Market Perform
January 7, 2020 6:12 AM ESTSVB Leerink analyst Dae Gon Ha initiates coverage on Apellis Pharmaceuticals (NASDAQ: APLS) with a Market Perform rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Apellis Pharmaceuticals... More
